These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 26378740)
1. 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads. Rombouts FJ; Tresadern G; Delgado O; Martínez-Lamenca C; Van Gool M; García-Molina A; Alonso de Diego SA; Oehlrich D; Prokopcova H; Alonso JM; Austin N; Borghys H; Van Brandt S; Surkyn M; De Cleyn M; Vos A; Alexander R; Macdonald G; Moechars D; Gijsen H; Trabanco AA J Med Chem; 2015 Oct; 58(20):8216-35. PubMed ID: 26378740 [TBL] [Abstract][Full Text] [Related]
2. Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain. Fuchino K; Mitsuoka Y; Masui M; Kurose N; Yoshida S; Komano K; Yamamoto T; Ogawa M; Unemura C; Hosono M; Ito H; Sakaguchi G; Ando S; Ohnishi S; Kido Y; Fukushima T; Miyajima H; Hiroyama S; Koyabu K; Dhuyvetter D; Borghys H; Gijsen HJM; Yamano Y; Iso Y; Kusakabe KI J Med Chem; 2018 Jun; 61(12):5122-5137. PubMed ID: 29733614 [TBL] [Abstract][Full Text] [Related]
3. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors. Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925 [TBL] [Abstract][Full Text] [Related]
4. β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. Hilpert H; Guba W; Woltering TJ; Wostl W; Pinard E; Mauser H; Mayweg AV; Rogers-Evans M; Humm R; Krummenacher D; Muser T; Schnider C; Jacobsen H; Ozmen L; Bergadano A; Banner DW; Hochstrasser R; Kuglstatter A; David-Pierson P; Fischer H; Polara A; Narquizian R J Med Chem; 2013 May; 56(10):3980-95. PubMed ID: 23590342 [TBL] [Abstract][Full Text] [Related]
5. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design. Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670 [TBL] [Abstract][Full Text] [Related]
6. Spirocyclic β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors: from hit to lowering of cerebrospinal fluid (CSF) amyloid β in a higher species. Hunt KW; Cook AW; Watts RJ; Clark CT; Vigers G; Smith D; Metcalf AT; Gunawardana IW; Burkard M; Cox AA; Geck Do MK; Dutcher D; Thomas AA; Rana S; Kallan NC; DeLisle RK; Rizzi JP; Regal K; Sammond D; Groneberg R; Siu M; Purkey H; Lyssikatos JP; Marlow A; Liu X; Tang TP J Med Chem; 2013 Apr; 56(8):3379-403. PubMed ID: 23537249 [TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745 [TBL] [Abstract][Full Text] [Related]